Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biomea Fusion, Inc.BMEA · Entity 6606 | Director · See Remarks | April 01, 2026 | April 03, 2026 |
| POLARITYTE, INC.PTE · Entity 117561 | Director | January 02, 2020 | January 06, 2020 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director | February 19, 2021 | February 23, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biomea Fusion, Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.49 · Expires 2036-03-31 | Direct | 452,512 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 452,512 · Balance 452,512 F1: The option shall vest and become exercisable in 16 substantially equal quarterly installments after April 1, 2026, such that the award will be fully vested and exercisable on April 1, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable in 16 substantially equal quarterly installments after April 1, 2026, such that the award will be fully vested and exercisable on April 1, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date.
POLARITYTE, INC.
Report date January 02, 2020 · Filed January 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option(Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.60 · Expires 2030-01-31 | Direct | 38,437 |
Reported balance
After 2020-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-01-02 · Grant · Acquired 38,437 · Balance 38,437 F1: This option was issued to the reporting person pursuant to the 2019 Equity Incentive Plan for annual director fees in the amount of $80,000. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was issued to the reporting person pursuant to the 2019 Equity Incentive Plan for annual director fees in the amount of $80,000.
Summit Therapeutics Inc.
Report date February 19, 2021 · Filed February 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.33 · Expires 2031-02-19 | Direct | 252,273 |
Reported balance
After 2021-02-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-19 · Grant · Acquired 25,000 · Balance 252,273 F2: Not applicable. F1: The option was granted on February 19, 2021. The shares underlying the option are scheduled to vest in full on December 31, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on February 19, 2021. The shares underlying the option are scheduled to vest in full on December 31, 2021.
F2: Not applicable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 01, 2018 Filed Nov 5, 2018 16:30 UTC | POLARITYTE, INC. PTE · Entity 117561 | GrantEmployee Stock Option (Right to Buy) · Derivative | 13,268 | $0.00 Strike: $15.24 | $0.00 |
DisclosureSEC source: 0001493152-18-015196 · ownership.xml · derivative · entry 1 Erdtmann Rainer M · CIK 0001455767 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,268 Underlying: Common Stock · 13,268 shares Expires 2028-10-31 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments beginning on December 1, 2018. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 16:15 UTC | POLARITYTE, INC. PTE · Entity 117561 | PurchaseCommon Stock | 6,680 | $17.42 | $116,365.60 |
DisclosureSEC source: 0001493152-18-013409 · ownership.xml · nonDerivative · entry 1 Erdtmann Rainer M · CIK 0001455767 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Zeigeist LLC Disclosed balance after: 61,846 F1 · shares: Mr. Erdtmann owns and controls Zeigeist LLC. Zeigeist and Mr. Erdtmann hold a 26.721% interest in Point Sur Investors LLC, which purchased the issuer's common stock on September 14, 2018. The number of shares purchased by Mr. Erdtmann and owned indirectly through Zeigeist is 26.721% of the total shares purchased by Point Sur Investors F2 · price: Represents the weighted average price for multiple purchases on the same day all within a price range between $17.24 and $17.50. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.